As announced at the beginning of the month, the European Medicines Agency (EMA) issued an opinion on Friday 19 November on the emergency use of Lagevrio (molnupiravir or MK 4482), the candidate treatment against Covid-19 that has been developed by the Merck laboratory (see EUROPE B12829A23).
This drug, which has now been under evaluation by the EMA for almost a month, has not yet been granted a European marketing authorisation.
However, since the health situation in the EU is particularly...